公司資料
Boston Scientific 股價、新聞與催化劑
- 股票代碼:
- BSX
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
51.43 USD (-0.77%)
收盤價
最後更新: 2026年8月17日
70.9B USD
市值
股價為何變動
As of Aug 17, 2026, BSX closed down 0.77% at $51.43. No new same-company headline was identified in the current news window.
公司概覽
Global Medical Technology Platform
Boston Scientific is a global medical technology company with products spanning cardiovascular care, endoscopy, urology, neuromodulation, interventional oncology, respiratory care, and gastrointestinal medicine. Its portfolio centers on high-performance devices and minimally invasive therapies designed to improve clinical outcomes while reducing the burden on healthcare systems.
Electrophysiology Franchise
Electrophysiology is a major innovation area for Boston Scientific. The FARAPULSE pulsed field ablation system has demonstrated advantages over antiarrhythmic drug therapy in persistent atrial fibrillation, while the FARAFLEX Mapping and PFA Catheter extends the platform toward integrated cardiac mapping and ablation.
Coronary, Structural Heart, and Embolization
The company also continues to broaden its interventional portfolio. Recent activity includes positive pivotal evidence for the SEISMIQ coronary intravascular lithotripsy catheter, FDA clearance of the TruSelect 2.6 Microcatheter, and strategic exposure to the SIEGEL transcatheter aortic valve replacement system through MiRus.
MedSurg Businesses
Outside cardiovascular care, Boston Scientific’s MedSurg segment provides technologies for endoscopy, urology, neuromodulation, and other minimally invasive procedures. This business mix reduces dependence on any single therapeutic area and gives the company multiple channels for new-product adoption.
Diversified Operating Base
Boston Scientific operates through its Cardiovascular and MedSurg segments, with additional businesses including Urology and Neuromodulation. The company expands its platform through internal R&D, strategic investments, and acquisition options, including its investment in MiRus and potential rights to acquire the SIEGEL TAVR business.
未來催化劑
- Enrollment has begun in the pivotal FARADIGM trial evaluating the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter in patients with paroxysmal or persistent atrial fibrillation.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。